Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,207 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Low Dose Drug A Clear all

Conditions: Chronic Kidney Disease
Interventions: Sodium Bicarbonate, Placebo, Exercise Training, Control to Exercise (Stretching); Drug · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Lower Back Pain
Interventions: CNTX-3001, Placebo; Drug
Lead sponsor: Centrexion Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Napa, California

Conditions: Cancer
Interventions: GSK1120212 plus everolimus; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Nashville, Tennessee • San Antonio, Texas

Conditions: Norovirus Gastroenteritis
Interventions: VXA-G1.1-NN Oral Vaccine; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 19 Years to 49 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Influenza Immunization
Interventions: Quadrivalent Influenza mRNA Vaccine MRT5413, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza High-Dose Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 682 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 28
States / cities: Chula Vista, California • Gardena, California • Long Beach, California + 24 more

Conditions: Healthy Volunteers
Interventions: TAK-788, Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Volunteer
Interventions: danoprevir, efavirenz, ritonavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Anesthesia, Pain, Amnesia
Interventions: Nitrous oxide, Peripheral Nerve Stimulation; Drug · Device
Lead sponsor: Keith M Vogt; Other
Eligibility: 18 Years to 59 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthspan Improvement, Aging, Longevity
Interventions: Rapamycin, Naltrexone, Metformin, NAD+, GSH, Infinite Supplement, Placebo/control, B12, Intervention: Guided Meditation Program, Control: Podcast Listening Activity, Control: Standard Exercise Regimen, Intervention: Structured Exercise Program; Drug · Dietary Supplement · Behavioral
Lead sponsor: AgelessRx; Industry
Eligibility: 60 Years to 80 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Follicular Lymphoma, Lymphoma
Interventions: Odronextamab; Biological
Lead sponsor: Gottfried von Keudell, MD PhD; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: LSD
Interventions: LSD, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 40 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Volunteers
Interventions: Avatrombopag maleate 40 mg; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Quality of Life, Fatigue
Interventions: UVL1000 Treatment Station, Normal Saline Solution, Peripheral Catheterization; Device · Drug
Lead sponsor: UVLrx Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 3,063 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Iron Deficiency
Interventions: Iron-dextran, Saline, Blood Donation, 24-hour PTR; Drug · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Autistic Disorder, Autism
Interventions: Placebo, Risperidone high dose, Risperidone low dose; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 20
States / cities: Dothan, Alabama • Phoenix, Arizona • Sacramento, California + 17 more

Conditions: Glioblastoma (GBM)
Interventions: BreakVax, Ipilimumab 2.5 mg, Pembrolizumab, Temozolomide (TMZ), Losartan and aspirin; Drug
Lead sponsor: BreakBio Corp; Industry
Eligibility: 18 Years to 72 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Achondroplasia
Interventions: BMN 333, Vosoritide Injection [Voxzogo]; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 9
States / cities: Oakland, California • Wilmington, Delaware • Chicago, Illinois + 6 more

Conditions: Nicotine Dependence
Interventions: Nicotine; Other
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Interventions: amifostine trihydrate, carboplatin, paclitaxel, radiation therapy; Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Functional Constipation (FC)
Interventions: plecanatide, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 29
States / cities: Birmingham, Alabama • Mobile, Alabama • Saraland, Alabama + 25 more

Conditions: Breast Cancer
Interventions: Molecular Breast Imaging, Conventional Mammography, Technetium (99mTc) sestamibi; Device · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years and older · Female only
Enrollment: 1,638 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Noonan Syndrome
Interventions: Vosoritide Injection; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 3 Years to 11 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 21
States / cities: Los Angeles, California • Orange, California • Aurora, Colorado + 18 more

Conditions: Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes, Drug Evaluation
Interventions: Mesalamine, Infliximab, Corticosteroids, 6-Mercaptopurine, Tacrolimus, Adalimumab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Immunoglobulin A Nephropathy, Glomerular Disease, IgAN
Interventions: Dose-Placebo, Low Dose-VIS649, Medium Dose-VIS649, High Dose-VIS649; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • Oxnard, California + 13 more

Search by objective public record fields.

Sympatholysis in Chronic Kidney Disease

Safety and PK of Intrathecal CNTX-3001 for Intractable Chronic Low Back Pain

A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects

Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Participants

A Study of Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir in Healthy Volunteers

Nitrous Oxide Neuroimaging

Combination Gerotherapeutic Interventions for Healthspan Improvement

Odronextamab in Low Tumor Volume Advanced FL

Drug Effects on Mood and Behavior - Expectancy

A Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat Meal

Safety and Feasibility of Polychromatic Light Emitting Diode for Peripheral Catheter Illumination During Peripheral Intravenous Delivery of Normal Saline

Donor Iron Deficiency Study - Red Blood Cells From Iron-deficient Donors: Recovery and Storage Quality

A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder

Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia

Smoked Nicotine Induced Changes in Hormone Function, Mood States and Behaviors

Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC

Low Dose Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts

A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment

Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome

Safety and Efficacy Study of VIS649 for IgA Nephropathy